Latest posts
-
ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS
IRVINE, CA, August 9, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The
-
PaxMedica to Join Fireside Chat with PCG Advisory Following Positive Top Line Results from PAX-HAT-301 Study
PaxMedica to discuss significance of Phase 3 study results Interview to be webcast on Tuesday, August 15, 2023, at 10:30 am ET TARRYTOWN, NY, August 8, 2023 – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD)
-
Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference
CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA, August 8, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte,
-
Oncocyte To Announce Second Quarter 2023 Financial Results
Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 3, 2023 – Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company